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HYPERICIN, A POLYCYCLIC  aromatic dione isolated from plants, is presently being clinically evaluated as an antiviral 
agent in the treatment of human immunodeficiency virus (HIV) infection. In addition, it is known to be a potent protein 
kinase C inhibitor. To evaluate its potential as an inhibitor of glioma growth, an established (U87) and low-passage 
glioma line (93-492) were treated with hypericin in tissue culture for a period of 48 hours after passage. Hypericin 
inhibited the glioma growth in a dose-related manner, with a marked inhibition of growth in the low-micromolar 
concentration range (e.g., in line U87 and low-passage line 93-492, a concentration of hypericin of 10 pmol/L 
produced 62 and 76%  decreases in [3H]thymidine uptake, respectively). Because the reported inhibitory effects of 
protein kinase C a re  enhanced by visible light, [3H]thymidine uptake was measured in both the presence and the 
absence of visible light. In glioma line A172, the presence of light slightly increased the inhibitory effect of hypericin. 
Moreover, an apoptosis (i.e., programmed cell death) assay was performed to determine whether the treatment of 
glioma cells with hypericin was cytostatic or cytocidal. Cells were harvested, and purified deoxyribonucleic acid 
(DNA) was analyzed by agarose gel electrophoresis. DNA from cells treated with hypericin for 48 hours exhibited 
a classical "ladder" pattern of oligonucleosome-sized fragments characteristic of apoptosis. These data suggest that 
the proven safe drug hypericin may have potential as an antiglioma agent; we suggest clinical trials. (Neurosurgery 
35:705-710, 1994)
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T
w o  aromatic p o ly cy c lic  diones, hypericin and pseudohy­
pericin, are d e r iv e d  from plants of the Hypericum family 
(Saint Joh nsw ort, H. perforatum). They have recently been 
reported to be h ig h ly  effective in preventing viral-induced 
m anifestations that fo llow  a variety of retrovirus infections 
both  in  vitro and in  v ivo  (16, 19, 20, 23). These com pounds 
probably interfere w it h  viral infection an d /or spread b y  direct 
inactivation of the v iru s or by preventing virus shedding, 
b u d d in g , or a ssem b ly  at the cell membrane (23, 32). Their 
adm inistration can com pletely prevent the rapid spleno­
m ega ly  induced by aggressive  m urine viruses; in vitro studies 
w ith  infected cell cu ltu res demonstrate that the com pounds 
effectively  inhibit th e  release of reverse transcriptase activity 
into the grow th m e d iu m  but do not affect total viral messenger 
ribonucleic acid le v e ls  or the expression of viral antigens 
w ith in  th e  cells (23). Such work has indicated very direct cel­
lular targets for th e  activ ity  of these drugs w ith limited sys­
tem ic toxicity. This p rop erty  distinguishes their m ode of action 
from that of the m ajor antiretrovirus group of nucleoside ana­
logues (23). A lthough the precise intracellular mechanisms for 
its antiviral effects are unknown, this encouraging laboratory 
work has propagated an evaluation of hypericin in a phase I 
trial for patients w ith  HIV infection (14, 25, 34).
M alignant gliom as possess very high protein kinase C (PKC) 
activity w hen  compared with nontransformed glia, which is 
strongly correlated to the growth rates of these tumor cells in  
vitro (5, 6). Surgically resected frozen human glioma speci­
mens also display elevated PKC activity w ithin the range of 
activity m easured in  established glioma lines (5). This elevated 
PKC activity may function as a target for the inhibition of 
glioma grow th in vitro (1, 4, 27) and is currently being evalu­
ated w ith  som e success in clinical trials for use as a chemo­
therapeutic target in v ivo  (2 ,7,8 ,35). The molecular structures 
of hypericin (Fig. 1 ) and pseudohypericin are similar to cal- 
phostin C, a relatively specific inhibitor of PKC (30, 31). 
Hypericin has been previously demonstrated to be a potent 
PKC inhibitor (30), a mechanism that has been hypothesized
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FIGURE 1. The structure of hypericin: 1,3,6,8,13-hexahy- 
droxy-10,11 -dimethylphenanthro[1,10,9,8-opqra]per- 
ylene-7,14-dione.
to explain som e of its antiviral activity. Hypericin, like cal- 
phostin C, interacts with the regulatory dom ain of the PKC 
enzym e (17, 18). These compounds, therefore, represent an 
alternative class of inhibitors of PKC, to be differentiated from  
those agents such as staurosporine, w hich are speculated to 
compete for adenosine 5'-triphosphate on the catalytic subunit 
of the enzyme.
Hypericin effectively crosses the blood-brain barrier, having 
previously been administered to humans as an antidepressant 
as long as 4 decades ago w ith apparent salutary effects (9). The 
ubiquitous availability of the Saint Johnswort plant w orldw ide  
and the relatively convenient and inexpensive bioextraction 
make this compound particularly attractive for use in  HIV- 
related disease and for central nervous system  antineoplastic 
applications.
We studied the effects of hypericin on the growth of both 
established and low-passage malignant glioma lines in vitro. 
W e show  here that hypericin inhibits the growth of malignant 
gliom as in vitro in a dose-related manner; furthermore, w e 
demonstrate that the compound induces a programm ed cell 
death (apoptosis) signal in these cells.
MATERIALS AND METHODS 
Glioma cell cultures
The previously characterized human m alignant glioma cell 
lines A172 and U87-MG were used in  this study (obtained from  
the American Type Culture Collection). The low -passage pri­
mary gliom a culture (93-492) w as established at our institution; 
this w as derived from glioblastoma tissue rem oved from a 
27-year-old patient. Lines were maintained in  25-cm2 tissue 
culture flasks in  Dulbecco's m odified Eagle's m edium  supple­
m ented w ith  10% fetal bovine serum, penicillin-streptomycin  
(100 u n its/m l; 10 jig /m l), and 10 m m ol/L  H epes buffered to 
a pH  of 7.0 (all m edium  constituents were purchased from  
Sigma Chemical Co., St. Louis, MO). Cells w ere grown at 37°C 
in  a hum idified 5% C 0 2 incubator. The established lines U87 
and A172 w ere routinely tested for mycoplasma contamination 
and were regularly passaged.
Glioma proliferation [3H]thymidine uptake assay
Our method for determining the rates of gliom a prolifera­
tion has been previously published (4, 6). After passage, each 
cell line w as seeded at a density of 104 cells in  40 pi of m edium  
on 12-mm glass coverslips placed in 24-w ell culture plates. 
Coverslips were previously coated w ith 10 p g /m l poly-L-ly- 
sine to facilitate cell adherence. Twelve hours later, after ad­
equate time for the cells to adhere to the coverslips, the w ells 
were flooded and washed w ith phosphate-buffered saline. 
After an addition of 1 ml of feeding m edium  (containing 10% 
fetal bovine serum) to each w ell, the PKC inhibitor hypericin  
(Fig. 1) (LC Service Corp., Woburn, MA) w as then added to the 
w ells at predetermined concentrations in replicates o f three. 
After a 48-hour incubation, w ells were pulsed  w ith  1 pCi of 
[3H ]thym idine/m l for a period of 6 hours before harvest. To 
measure thymidine incorporation, the coverslips w ith  adher­
ent cells were washed 4 times w ith phosphate-buffered saline 
and were placed in scintillation vials containing 5 m l of scin­
tillation fluid (Cytoscint; ICN Chemical, Irvine, CA) for de­
termination in a /3-counter. It has been previously dem on­
strated that uptake of [3H]thym idine into cells by this 
technique is a reliable index of D NA  synthesis (1).
DNA fragmentation (apoptosis) assay
After treatment with hypericin for 48 hours in 25-cm2 tissue  
culture flasks at the same cell density and m edium  as above, 
washed cell pellets were resuspended in lysis buffer (0.5% 
sodium dodecyl sulfate, 0.1 m ol/L  NaCl, 10 m m o l/L  N,N’~ 
l,2-ethanedylbis[N-(carboxymethyl)glycine], 0.01 m o l/L  Tris- 
HC1, pH 8.0) in the presence of 0.1 m g /m l proteinase K for 18 
to 24 hours at 37°C. The samples were extracted tw ice w ith  
phenol:chloroform/isoamyl alcohol and precipitated by  the 
addition of 0.10 volum e of 2 m o l/L  sodium  acetate and 2.5 
volum es of ethanol. After resuspension in 10 m m o l/L  Tris-1 
m m ol/L  N,W '-l,2-ethanedylbis[N-(carboxymethyl)glycine], 
pH  7.4, sam ples were treated w ith DNase-free R Nase for 2 
hours at 37°C. After reextraction and reprecipitation, sam ples 
were dissolved in 10 m m ol/L  Tris, 0.1 m m o l/L  N,N'-1,2- 
ethanedylbis[N-(carboxymethyl)glycine], pH  7.4. D N A  con­
centration w as determined by A 260 m easurem ents using a 
Beckman DU-640 spectrophotometer. Equal am ounts of D N A  
were electrophoresed on a 1.2% agarose gel containing 0.5 
m g /m l ethidium  bromide and visualized by  UV fluorescence.
RESULTS 
Hypericin effects upon glioma proliferation
To assess the effects of hypericin on the proliferation of 
gliomas, the drug was added to glioma cultures for a period  
of 48 hours, after which time [3H]thym idine uptake w as d e­
termined (Fig. 2, A and B). Hypericin inhibited the grow th of 
both the established and low-passage tumors in  a dose-related  
manner.
To determine the effects of visible light on the grow th in­
hibition produced by hypericin, cultures w ere treated under 
dark and in  the presence of visible light. Representative 
[3H]thymidine uptake is shown for glioma line A172 in Figure
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FIGURE 2. [3H]Thymidine uptake after the addition of hypericin to the glioma-established cell line U87 (4) and low-passage 
malignant glioma line 93-492 (B) cultures for a period of 48 hours in vitro. Note the dose-related significant decrease in 
thymidine uptake after the treatment of each of the glioma cell lines. In a similar manner, the [3H]thymidine uptake of 
glioma line A172 is significantly inhibited by hypericin in the dark but is facilitated under light conditions (C). Values repre­
sent mean + standard error of the mean of triplicate values (**, significantly different from control values, using one-way 
analysis of variance, Duncan's multiple comparison with P <  0.01).
2C. Growth inhibition w as som ewhat facilitated in the pres­
ence of visible light.
Hypericin induces programmed cell death (apoptosis) 
in malignant glioma cell lines
Treatment of A172 gliom a cells w ith 10 p m ol/L  hypericin  
for a 48-hour period resulted in significant cell detachment. 
Floating cells w ere perm eable to trypan blue dye, indicating 
that they had lost viability. After adherent and floating cells 
were collected and pooled, D N A  was purified and analyzed by  
agarose gel electrophoresis. The results in Figure 3 reveal a 
classical ladder pattern of oligonucleosom al-sized fragmented  
DNA, the m olecular hallmark of apoptosis, for glioma cells 
treated with hypericin. N o  significant degradation of D N A  
was observed in untreated cells, as evidenced by the presence 
of an intensely stained band of high molecular w eight D N A  
and the lack o f ethidium  bromide-stained material in the re­
gion of the gel corresponding to low-m olecular w eight D N A . 
As a positive control for the induction of apoptosis, glioma cells 
treated w ith 100 n g /m l tum or necrosis factor-a also displayed  
a prominent ladder of fragmented DNA. Comparable results 
were observed w hen  gliom a cells were treated w ith hypericin  
in the dark (data not shown).
DISCUSSION
Hypericin is currently being evaluated as an antiviral agent 
in the treatment o f HIV infection (14, 25, 34). Hypericin has 
been regarded as a prom ising potential antiacquired im m u­
nodeficiency syndrom e drug since 1988, w hen it was reported  
that a single injection of this com pound prevented sp leno­
megaly and death in  m ice infected w ith Friend leukemia virus. 
Administration of this com pound to mice at the low  doses 
sufficient to prevent retroviral-induced disease appears d e­
void of undesirable side effects (23). The exact mechanism of 
the antiviral activity of the aromatic polycyclic diones has not 
been elucidated; how ever, hypericin and pseudohypericin  
have recently been identified as relatively specific inhibitors o f
TNF HY
FIGURE 3. Hypericin induces apoptosis in malignant glioma 
cell lines. Treatment of glioma cell line A172 with hyperi­
cin and DNA isolation are described under Materials and 
Methods. DNA isolated from A172 cells in the absence of 
hypericin (lane C) and in the presence of 10 pmol/L hyperi­
cin (lane HY) were electrophoresed in 1.2% agarose and 
stained with ethidium bromide. Note the presence of oligo- 
nucleosome-sized fragments producing a classic ladder 
pattern in the lane containing DNA from treated cells (ar­
rows). As a positive control for apoptosis, A l 72 cells 
were treated with 100 ng/ml tumor necrosis factor-a (lane 
TNF). The sizes of oligonucleosomal fragments were de­
termined by comparison to DNA size markers in lane M.
PKC (30), w hich  m ay represent a potential candidate for such  
activity. Both of the com p oun ds inhibited PKC from rat brain 
w ith IC50 values of 1.7 and 15 p g /m l for hypericin or 
pseudohypericin , respectively, w ith  little activity against PKA  
or calm odulin -dependent protein kinases at m uch higher dos­
ages (30). The antiretroviral activity of hypericin is greater than 
that of pseudohypericin , w hich  is also consistent w ith their 
inhibitory activity against PKC (30).
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It has previously been demonstrated that PKC activity and 
the rate o f proliferation of glioma lines are highly coupled in 
vitro (5,6). The very high activity characteristic of gliom as may 
provide a target for novel therapies using PKC inhibitors. 
Initial studies using tw o well-characterized nonspecific PKC 
inhibitors, tamoxifen and staurosporine, revealed a potent in­
hibitory effect of these drugs on the proliferation of low -pas­
sage primary and established glioma cell lines (1, 6, 27). These 
findings prompted the current investigation of hypericin, an­
other anti-PKC agent, on glioma cells.
The results from the present study indicate that hypericin  
m ay inhibit the growth of glioma cell lines in vitro in  a dose- 
related manner as measured by thymidine uptake. We also 
find that hypericin is a potent inducer of glioma cell death, 
w hich is accompanied by extensive degradation of genom ic 
D N A  into discrete oligonucleosomal fragments characteristic 
of apoptosis. Hypericin previously has been reported to exert 
both antiproliferative and cytotoxic effects on tumor cells (23,
30), these actions being attributed to inhibition of PKC activity 
by hypericin. Our studies confirm and extend this hypothesis 
in that PKC had been implicated as a negative regulator of 
apoptosis (12), which could account for our observation that 
hypericin induced an apoptotic response in  glioma cells. A d­
ditional studies are warranted to establish that the induction  
of apoptosis by hypericin is not the result of other described 
actions of the drug, including membrane damage (11), gen­
eration of singlet oxygen and free radicals (10), and inactiva­
tion of mitochondrial enzym es and impairment of m itochon­
drial function (33). However, the cytotoxic activity of the 
com pound in the present study is within the sam e concentra­
tion range as its PKC inhibitory activity, w hich suggests that 
the cytotoxic activity may be the result of inhibition o f PKC and  
subsequent induction of apoptosis in these cells.
H ypericin has a long and w ell-docum ented history as a 
photodynam ic compound. In previous studies, both the anti­
viral (22, 28) and antitumor (33) effects of hypericin are mark­
ed ly  enhanced by visible light. Data from the present study  
indicate thatthe inhibitory effect on glioma growth is increased  
approximately 13% by visible light, indicating that light may  
facilitate, but is not essential for, the antitumor effect in  vitro. 
A lthough the doses necessary for antiviral and anti-PKC ac­
tivity are less than those associated with clinical hypericism  
(ingestion of large amounts of hypericin from plants of the 
Hypericum  genus by grazing animals causes skin irritation and 
fever), the photosensitization effect m ust be considered w ith  
clinical use (13,15).
Data from the present study indicate that the drug inhibits 
gliom a growth at least as w ell as tamoxifen in  vitro (IC50 values 
of <10 v s 10 pm ol/L ) (1), an agent currently being evaluated  
for efficacy against malignant gliomas. A n initial phase I trial 
of very high dose tamoxifen at our institution indicates that 
approxim ately 35 to 40% of patients w ith recurrent m alignant 
gliom as (anaplastic astrocytoma or glioblastoma multiforme) 
stabilize or respond to high-dose tamoxifen therapy (7, 8). 
These encouraging results suggest potential for PKC-directed 
therapy and have led to the search for other well-tolerated  
com pounds with increased potency and specificity for PKC. 
Tam oxifen may be considered an only m oderately potent
agent, as studies have illustrated that other kinase inhibitors, 
such as staurosporine, possess approxim ately 1000-fold higher 
activity against PKC and glioma growth (1,4). The previously  
published antiviral activity of hypericin is in the sam e con­
centration range as the growth inhibitory effects upon  gliom a  
cell in vitro demonstrated in the present study, suggesting that 
this agent may be suitable for future chem otherapeutic trials 
in hum ans w ith malignant gliomas. H ypericin, like m any other 
anticancer drugs, may kill tumor cells by initiating a pro­
gram m ed molecular pathway for cell suicide, designated ap­
optosis (3). Its photodynamic effect may potentiate its efficacy 
in such applications.
Hypericin is also a potent antidepressant that has been clini­
cally u sed  in the past, has been w ell tolerated, and has not 
caused significant side effects (9 ,26,29). In a study of patients 
w ith clinical depression who were adm inistered hypericin, the 
excretion of urinary metabolites of noradrenaline and dopam ­
ine increased significantly, w hich paralleled a quantitative im ­
provem ent in major depressive sym ptom s (24). The m echa­
nism  for its antidepressant action is unknow n, but this work  
has indicated that the drug effectively crosses the blood-brain  
barrier. A  distribution half-life of 2.0 hours and an elim ination  
half-life of 38.5 hours have been calculated in humans; in 
addition, a method for rapid and specific m easurem ent of the 
drug by high-performance liquid chrom atography for clinical 
and pharmokinetic studies is available (21). H ypericin has also  
been synthesized, which offers an alternative supply  of the 
com pound. Given the results of the present study, the agent is 
proposed for phase I study for safety and possible efficacy in 
patients harboring recurrent malignant gliom as after standard  
therapy.
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COMMENTS
These results are preliminary, and w e think that more ex­
perim ents should be performed. In this article, C ouldw ell, et 
al. describe the effect of hypericin, a polycyclic aromatic dione 
and know n antiviral agent, on tw o glioma cell lines. Specifi­
cally, they describe inhibition of [3H ]thym idine uptake of 
gliom a cells after treatment w ith hypericin for 48 hours. This 
inhibition of [3H ]thym idine uptake w as a dose-related phe­
nom enon w ith  a m axim um  effect at 10 p m ol/L  and minimal 
effect at 1 p m o l/L  concentration. The authors report that this 
effect w as cytocidal, because they analyzed the D N A  of cells 
after treatment and found a specific ladder pattern of oligo- 
nucleosom e-sized  fragments characteristic of cell death. They 
suggest that the hypericin effect is probably because of its 
function as a protein kinase C inhibitor.
It is unclear whether the observed effects are specific effects 
of hypericin on  the gliom a tumor cells or whether they rep­
resent nonspecific toxic effects that w ould be com m on to any 
cell type. In addition, this could be (as the authors briefly 
discussed) a membrane effect of hypericin rather than inhibi­
tion of protein kinase C activity. To better exam ine these pos­
sibilities, further experim ents should be done w ith the same
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concentrations of hypericin in control normal glial cells or 
other normal cells, such as fibroblasts, to show  that there is a 
specific effect on the tumor cells. In addition, a time course of 
hypericin at low er doses, such as 1 p m ol/L , w hich is not 
im mediately toxic to the cells, should be performed and the 
numbers of cells should be counted. More thorough experi­
ments w ould  determine the following: 1) whether there is an 
inhibitory effect at lower doses for longer periods of time, and 
2) the effect of longer incubations at the sam e low  dose on 
m orphology (phenotype) of these cells.
These data are preliminary; the effectiveness of hypericin in 
glioma cell cultures has not been established. Clinical studies 
w ould be premature until more cell culture studies in more 





This article provides preliminary preclinical support for the 
phase I study of hypericin in patients w ith recurrent malignant 
gliomas. The drug is novel and has a demonstrated capacity to 
inhibit protein kinase C, which seem s to b e consistently over­
expressed in malignant gliomas. A  clinical trial w ill need fur­
ther support from the laboratory, including studies in  one of 
the many rod ent brain tumor m odels that are readily available. 
Years ago, Dr. Charles W ilson said som ething to the effect that 
we w ill never cure a human brain tumor w ith  chemotherapy  
until w e cure one in rats. Perhaps this is as true now  as it 
sounded then. It w ill be important to have strong data to 
support the use of this apparently nontoxic drug in humans.
Nicholas A. Vick
Evanston, Illinois
C ouldw ell and collegues continue their w ork on inhibitors 
of protein kinase C (PKC). Elevated levels of PKC are found  
in gliom as both in vitro and in vivo, and inhibitors of PKC 
appear to m odulate growth in  a dose-dependent manner. 
Promising phase I and II data regarding tam oxifen, a nonspe­
cific inhibitor of PKC, in the setting of recurrent malignant 
gliomas provide compelling reasons to continue to evaluate 
other such agents. Hypericin, an antiviral agent just beginning  
phase I clinical testing in patients w ith acquired im m unodefi­
ciency syndrom e, has been show n to be a potent inhibitor of 
PKC, possibly b y  interactions w ith the regulatory dom ain of 
the PKC enzym e. Data already existed to  support that this 
agent crosses the blood-brain barrier; all that remained w as to
dem onstrate that hypericin indeed m odulated gliom a growth. 
C ouldw ell et al. have demonstrated that hypericin inhibits 
gliom a proliferative cell growth in vitro, as m easured by tri- 
tiated thym idine uptake studies. Program m ed cell death ap­
peared to be induced by hypericin as w ell. The m echanism  of 
apoptosis in this experiment is uncertain but is postulated to 
be secondary to PKC inhibition as w ell, w ith  PKC acting as a 
negative regulator of apoptosis. The authors d iscuss the role of 
hypericin as a photodynam ic com pound and sh ow  a sm all 
enhancem ent in  the antiproliferative effect w ith  the addition of 
visible light.
Given the lack of significant toxicities in previous w ork w ith  
patients w ith  depressive disorders, this agent does appear to 
be a candidate drug for phase I or II testing in recurrent g lio ­
mas. Further w ork is proposed to further elucidate the specific 
m echanism s of apoptosis and PKC inhibitory activity. A l­
though the photodynam ic effect appears to be m easurable in 
the laboratory, one wonders how  to exploit this feature in 
clinical trials. It is reasonable to hope that new er, non toxic 
therapies w ill em erge as a consequence of straightforward, 
translationally based work, such as that presented b y  C ould­
w ell et al. C om bination therapies that include antiproliferative 
agents w ith  agents that selectively induce apoptosis or agents 
that "differentiate" tumor cells toward a m ore norm al pheno­
typic state w ou ld  be a w elcom ed change from nonselective, 
highly toxic chemotherapies that have m arginal efficacy.
Michael Prados
San Francisco, California
The need for effective agents for the treatment of m alignant 
gliom as is apparent. It is remarkable h o w  few  chem othera­
peutic agents have been show n to have therapeutic efficacy for 
this tum or type. There is major interest in the developm ent of 
novel agents and n ew  insights that w ill offer additional 
therapy options.
This w ork w ell fits these needs. A  new  type of agent, using  
a novel m echanism  with a different end point, has been  studied  
in  a hum an cellular-based assay system . This approach is a 
m odel for a variety of research fronts.
The agent hypericin appears to have its effects via the PKC 
pathw ay, and its effect is achieving apoptosis rather than cy­
totoxicity. A poptosis, or programmed cell death, is in  m any  
w ays a m ore appealing chemotherapy. A gents such as carmus- 
tine cause im m ediate cell death, even on  contact in  culture 
studies. H ypericin  has an apoptotic effect.
Paul L. Kornblith
Pittsburgh, Pennsylvania
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